enGene Inc. Warrants
(ENGNW)
undefined
undefined%
At close: undefined
0.93
0.00%
After-hours Jan 06, 2025, 03:29 PM EST
Company Description
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.
Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
The company was founded in 2023 and is based in Saint-Laurent, Canada.
enGene Inc. Warrants
| Country | n/a |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Ronald H. W. Cooper |
Contact Details
Address: No Address available No city data available, | |
| Website | n/a |
Stock Details
| Ticker Symbol | ENGNW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001980845 |
| CUSIP Number | n/a |
| ISIN Number | n/a |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ronald H. W. Cooper | Chief Executive Officer & Director |
| David Ryan Daws | Chief Financial Officer & Head of Business Development |
| Joan Connolly | Chief Technology Officer |
| Lee G. Giguere | Chief Legal Officer & Corporate Secretary |
| Dr. Alex Nichols Ph.D. | Chief Strategy & Operations Officer |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Raj Pruthi F.A.C.S., M.D., M.H.A. | Chief Medical Officer |
| John C. Brown D.Sc., FRSC, Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Paul Erickson | Non-Executive Director |
| Sharon Tan | Vice President of Project Management & Head of Program Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 8-K | Current Report |
| Dec 20, 2024 | 424B5 | Filing |
| Dec 19, 2024 | 10-K | Annual Report |
| Dec 19, 2024 | 8-K | Current Report |
| Nov 21, 2024 | 424B3 | Filing |
| Nov 21, 2024 | 424B3 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | S-3 | Filing |